Mayo Clinic Q and A: Glaucoma -- the 'silent thief of sight'
DEAR MAYO CLINIC: During my recent eye exam, the eye doctor used a machine to blow a puff of air into each of my eyes. It felt like I was in a video game, but I was the target. It didn't hurt, but it did startle me. What does this test measure and how is it helpful in evaluating my vision? Is this something I need to have regularly repeated? ANSWER: Vision tests are always important to… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 4, 2023 Category: Databases & Libraries Source Type: news
FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Iyuzeh™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States
LEXINGTON, Massachusetts– December... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2022 Category: Drugs & Pharmacology Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma
TARRYTOWN, N.Y., Dec. 8, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 8, 2022 Category: Drugs & Pharmacology Source Type: news
Prescribed anti-glaucoma medication consumption and road traffic crash - Lu L, Contrand B, Schweitzer C, Gadegbeku B, Delcourt C, Lagarde E.
BACKGROUND: Glaucoma is one of the leading causes of visual impairment worldwide. Influence of visual defects associated with this condition, as well as potential side effects of anti-glaucoma medications on driving may be a relevant traffic safety concern... (Source: SafetyLit)
Source: SafetyLit - December 5, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
South Africa: International Day of Persons With Disabilities - 'It Always Seems Impossible Until It's Done'
[UCT] Teenagers the world over will agree: entering your teen years is much like a rite of passage. It's a steppingstone to young adulthood and many 12-year-olds eagerly anticipate their 13th birthday. It was no different for Benedict Leteane. But, in 1999, a few months after his 13th birthday, congenital glaucoma claimed his eyesight and changed the trajectory of his life forever. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 2, 2022 Category: African Health Source Type: news
Mean Length of Preclinical Detectable Phase of Glaucoma & gt;10 Years
TUESDAY, Nov. 29, 2022 -- The mean length of the preclinical detectable phase (PCDP) of open-angle glaucoma is estimated to be over 10 years, according to a study published online Nov. 23 in JAMA Ophthalmology.
Johan Aspberg, M.D., from Lund... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2022 Category: Pharmaceuticals Source Type: news
Why Mark Cuban Is Selling Anti-Fungal Ointment for $7.34
Mark Cuban, the tech titan, Dallas Mavericks owner, and star of ABC’s Shark Tank, moves through the world like a friendly great white, all teeth and eyes and relentless motion. When we meet on an October morning at his office in the Mavericks’ headquarters, the serial entrepreneur, 64, is wearing a long-sleeved T-shirt advertising his last investment: Mark Cuban Cost Plus Drug Co. I was there to find out why a guy who’s made billions in tech, won an NBA championship, and become perhaps the most popular businessman on reality TV was spending his time and fortune hawking generic anti-fungal medications onli...
Source: TIME: Health - November 17, 2022 Category: Consumer Health News Authors: Charlotte Alter/Dallas Tags: Uncategorized Health Care Magazine uspoliticspolicy Source Type: news
Upstate researcher awarded over $2M to begin first studies of TM cells ’ mechanical memory, improving understanding of its role in glaucoma
Dr Samuel Herberg will study how and why trabecular meshwork cells in the eye react differently to stressors when an individual has glaucoma. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - November 14, 2022 Category: Universities & Medical Training Tags: News Research Source Type: news
'Nothing could be done': Singer Andrea Bocelli on his lifelong health battle - symptoms
The Italian singer has never let his congenital glaucoma stand in the way of his success. (Source: Daily Express - Health)
Source: Daily Express - Health - November 14, 2022 Category: Consumer Health News Source Type: news
Licensing authority revokes ban on production of five medicines by Ramdev-owned Divya Pharmacy
The Uttarakhand Ayurveda and Unani Licensing Authority on Saturday revoked the order asking Yoga guru Ramdev's Divya Pharmacy to stop the production of five medicines for diabetes, blood pressure, goitre, glaucoma and high cholesterol. It issued a fresh order allowing the firm to continue the production of these medicines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 13, 2022 Category: Pharmaceuticals Source Type: news
The effects of visual field loss from optic disc drusen on performance in a driving simulator - Bro T, Andersson J.
The purpose of this study was to compare the driving simulator performance of participants with visual field loss (VFL) from optic disc drusen (ODD) with a normally sighted control group and a group of individuals with glaucoma. Data on performance and saf... (Source: SafetyLit)
Source: SafetyLit - November 12, 2022 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Poor Sleep Quality Tied to Higher Risk for Glaucoma
FRIDAY, Nov. 4, 2022 -- Many patterns of poor sleep quality are associated with an increased risk for glaucoma, according to a study published online Nov. 1 in BMJ Open.
Cun Sun, from Beijing Huimin Hospital, and colleagues examined the association... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 4, 2022 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bad Sleep Might Raise Your Odds for Glaucoma
WEDNESDAY, Nov. 2, 2022 -- Poor sleep may be linked to glaucoma, a leading cause of blindness, new research suggests.
The study drew on a database of more than 400,000 people to explore links between sleep and vision loss.
Glaucoma is marked by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2022 Category: General Medicine Source Type: news
